Table 2.

Thirty-day clinical outcome in patients undergoing TAVI and AVR

	TAVI	AVR	p-value
	n = 235	n = 24
Mortality, n (%)
- All-cause	20 (9)	2 (8)	1.0
- Cardiovascular cause	13 (6)	2 (8)	0.64
Myocardial infarction, n (%)
- All	3 (1)	1 (4)	0.32
- Periprocedural (<72 h)	2 (1)	0	1.0
Cerebrovascular complication, n (%)
- All1	20 (9)	2 (8)	1.0
- Major stroke	11 (5)	1 (4)	1.0
Vascular complication, n (%)
- All	42 (18)	0	0.036
- Major	24 (10)	0	0.14
Bleeding complication, n (%)
- All	67 (29)	2 (8)	0.049
- Life-threatening or disabling	21 (9)	2 (8)	1.0
Acute kidney injury, n (%)
- All	40 (17)	8 (33)	0.058
- Stage III	5 (2)	2 (8)	0.13
Cardiac re-intervention, n (%)
- AVR	1 (1)	0	1.0
- BAV	1 (1)	0	1.0
- Other2	1 (1)	2 (8)	0.023
New pacemaker implantation
- All	48 (21)	1 (4)	0.056
- For 3rd degree AV block	40 (17)	0	0.032
New atrial fibrillation	9 (5)	2 (11)	0.60
Repeat hospitalisation, n (%)3	3 (1)	0	1.0
Combined 30-day safety endpoint, n (%)4	55 (24)	6 (25)	1.0

AV atrioventricular, AVR aortic valve replacement, BAV balloon aortic valvuloplasty

Mutually non-exclusive analysis (≥1 event/patient possible)

¹Including TIA

²Closure of severe paravalvar aortic regurgitation with Amplatzer closure device (n = 1) in TAVI group and resternotomy for severe aortic regurgitation (n = 1) and bleeding (n = 1) in AVR group

³For symptoms of valve-related dysfunction or cardiac decompensation

⁴Composite all-cause mortality, major stroke, major vascular complication, life-threatening bleeding, acute kidney injury - stage 3, peri-procedural myocardial infarction, repeat procedure for valve-related dysfunction (surgical or interventional)